Medicare Enrolled

Dr. Lara Gross, MD

Allergy & Immunology · Dallas, TX
Speaking/Promotional
5499 GLEN LAKES DR, Dallas, TX 75231
2146911330
In practice since 2013 (12 years)
NPI: 1811331705 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gross from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gross? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Gross

Dr. Lara Gross is an allergy & immunology in Dallas, TX, with 12 years in practice.

Between the years covered by Open Payments, Dr. Gross received a total of $97,768 from 33 pharmaceutical and/or device companies across 511 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in allergy & immunology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Gross is High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 12 years in practice$ $97,768 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$97,768
Total received (2018-2024)
Avg $13,967/year across 7 years
Top 5% in TX for allergy & immunology
33
Companies
511
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$50,704 (51.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$37,636 (38.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,428 (9.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$62,698
2023
$16,644
2022
$11,037
2021
$3,883
2020
$1,211
2019
$1,758
2018
$536

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ALK-Abello, Inc
$42,799
GENZYME CORPORATION
$15,236
Dermavant Sciences, Inc.
$9,742
Incyte Corporation
$5,799
AstraZeneca Pharmaceuticals LP
$5,100
Novartis Pharmaceuticals Corporation
$4,495
Regeneron Healthcare Solutions, Inc.
$3,018
Regeneron Pharmaceuticals, Inc.
$2,684
Optinose US, Inc.
$2,440
Genentech USA, Inc.
$2,172
GlaxoSmithKline, LLC.
$948
Grifols USA, LLC
$434
Blueprint Medicines Corporation
$421
kaleo, Inc.
$334
Takeda Pharmaceuticals U.S.A., Inc.
$314
SANOFI-AVENTIS U.S. LLC
$265
Octapharma USA, Inc.
$235
Pharming Healthcare, Inc.
$192
Merck Sharp & Dohme LLC
$157
Boehringer Ingelheim Pharmaceuticals, Inc.
$155
Teva Pharmaceuticals USA, Inc.
$149
Amgen Inc.
$121
PFIZER INC.
$100
Covis Pharma GmBH
$86
Genentech, Inc.
$84
Shire North American Group Inc
$68
ABBVIE INC.
$60
Hikma Pharmaceuticals USA
$39
HOSPIRA, INC.
$35
NOVARTIS PHARMACEUTICALS CORPORATION
$30
BioCryst Pharmaceuticals, Inc.
$22
LEO Pharma Inc.
$22
Almirall LLC
$12
Top 3 companies account for 69.3% of total payments
Associated products mentioned in payments ›
ADBRY · AIRSUPRA · AJOVY · ALVESCO · AUVI-Q · AYVAKIT · BREZTRI · BREZTRI AEROSPHERE · CUTAQUIG · CUVITRU · DUPIXENT · EUCRISA · FASENRA · Gamunex-C · Grastek · HYQVIA · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OPZELURA · Odactra · Otiprio · QVAR · RINVOQ · RUCONEST · Ragwitek · Ryaltris · SHINGRIX · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · TAKHZYRO · TAPINAROF · TEZSPIRE · TRELEGY ELLIPTA · VERDESO · XOLAIR · Xembify · Xhance · Xolair
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (52%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in allergy & immunology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for allergy & immunology in TX.

Looking for a allergy & immunology in Dallas?
Compare allergy & immunologys in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse allergy & immunologys nearby

Geographic Context

Allergy & Immunologys within 10 mi
66
Per 100K population
2.5
County median income
$74,149
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL DALLAS
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data— No dataN/A
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Gross is a allergy & immunology, and high industry engagement (speaking/promotional, top 5%).

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Gross receive payments from pharmaceutical companies?
Yes. Dr. Gross received a total of $97,768 from 33 companies across 511 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Gross) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →